The Baseline Tumor Size is an independent prognostic Factor for the progression-free but not the Overall Survival after Ipilimumab in Patients with metastatic malignant Melanoma

被引：0
|
作者：
Angelova, D. [1 ]
Weide, B. [2 ]
Heppt, M. [3 ]
Berking, C. [3 ]
Tietze, J. [1 ]
机构：
[1] Klinikum Augsburg, Dermatol, Augsburg, Germany
[2] Univ Hautklin Tubingen, Dermatol, Tubingen, Germany
[3] Ludwig Maximilians Univ Munchen, Dermatol, Munich, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2018年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P125
引用
收藏
页码：76 / 76
页数：1
相关论文
共 50 条
  • [21] PROGRESSION-FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER
    Beauchemin, C.
    Cooper, D.
    Lapierre, M.
    Yelle, L.
    Lachaine, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 119 - 120
  • [22] Validation of Serum Amyloid α as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients
    Vermaat, Joost S.
    Gerritse, Frank L.
    van der Veldt, Astrid A.
    Roessingh, Wijnand M.
    Niers, Tatjana M.
    Oosting, Sjoukje F.
    Sleijfer, Stefan
    Roodhart, Jeanine M.
    Beijnen, Jos H.
    Schellens, Jan H.
    Gietema, Jourik A.
    Boven, Epie
    Richel, Dick J.
    Haanen, John B.
    Voest, Emile E.
    EUROPEAN UROLOGY, 2012, 62 (04) : 685 - 695
  • [23] Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients With Metastatic Renal Cell Carcinoma
    Halabi, Susan
    Rini, Brian
    Escudier, Bernard
    Stadler, Walter M.
    Small, Eric J.
    CANCER, 2014, 120 (01) : 52 - 60
  • [24] Changes in Tumor-Blood Ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
    Weber, M.
    Pettersson, O.
    Seifert, R.
    Schaarschmidt, B. M.
    Fendler, W. P.
    Rischpler, C.
    Lahner, H.
    Herrmann, K.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S80 - S80
  • [25] Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival
    James X. Chen
    Steven Rose
    Sarah B. White
    Ghassan El-Haddad
    Nicholas Fidelman
    Hooman Yarmohammadi
    Winifred Hwang
    Daniel Y. Sze
    Nishita Kothary
    Kristen Stashek
    E. Paul Wileyto
    Riad Salem
    David C. Metz
    Michael C. Soulen
    CardioVascular and Interventional Radiology, 2017, 40 : 69 - 80
  • [26] Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-free Survival and Overall Survival
    Chen, James X.
    Rose, Steven
    White, Sarah B.
    El-Haddad, Ghassan
    Fidelman, Nicholas
    Yarmohammadi, Hooman
    Sze, Daniel
    Salem, Riad
    Metz, David
    Soulen, Michael C.
    PANCREAS, 2016, 45 (03) : 473 - 473
  • [27] EVALUATION OF PROGNOSTIC FACTORS OF OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
    Bramuzzo, I.
    Gerussi, A.
    Maier, S.
    Bianco, C.
    Romanin, A.
    Pasini, C. Laghi
    Barghini, V.
    Scata, L.
    Donnini, D.
    Uzzau, A.
    Vit, A.
    Sechi, L. A.
    Soardo, G.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E217 - E217
  • [28] Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival
    Chen, James X.
    Rose, Steven
    White, Sarah B.
    El-Haddad, Ghassan
    Fidelman, Nicholas
    Yarmohammadi, Hooman
    Hwang, Winifred
    Sze, Daniel Y.
    Kothary, Nishita
    Stashek, Kristen
    Wileyto, E. Paul
    Salem, Riad
    Metz, David C.
    Soulen, Michael C.
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2017, 40 (01) : 69 - 80
  • [29] Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
    Manuel Weber
    Olof Pettersson
    Robert Seifert
    Benedikt M. Schaarschmidt
    Wolfgang P. Fendler
    Christoph Rischpler
    Harald Lahner
    Ken Herrmann
    Anders Sundin
    European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51 : 841 - 851
  • [30] Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
    Weber, Manuel
    Pettersson, Olof
    Seifert, Robert
    Schaarschmidt, Benedikt M.
    Fendler, Wolfgang P.
    Rischpler, Christoph
    Lahner, Harald
    Herrmann, Ken
    Sundin, Anders
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (03) : 841 - 851
12345